A retrospective review assessing virologic response to Brincidofovir in pediatric, CD34+ selected allogeneic hematopoietic stem cell transplant (HCT) recipients with disseminated adenovirus infection
Latest Information Update: 26 Oct 2017
Price :
$35 *
At a glance
- Drugs Brincidofovir (Primary)
- Indications Adenovirus infections
- Focus Therapeutic Use
- 26 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017